The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Abstract
Purpose: The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower than 10 g/dL, leukocytes higher than 25 × 10 9 /L, circulating blasts ≥ 1%, and constitutional symptoms. The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status. Patients and Methods: Mayo Clinic databases for PMF were used to identify patients with available bone marrow histologic and cytogenetic information. Results: Seven hundred ninety-three consecutive patients were selected and divided into two groups based on whether or not their referral occurred within (n = 428; training set) or after (n = 365; test set) 1 year of diagnosis. Multivariable analysis identified DIPSS, unfavorable karyotype, platelets lower than 100 × 10 9 /L, and transfusion need as independent predictors of inferior survival. Hazard ratio (HR) –weighted adverse points were assigned to these variables to develop a composite prognostic model using the training set. The model was subsequently validated in the test set, and its application to all 793 patients resulted in median survivals of 185, 78, 35, and 16 months for low, intermediate-1 (HR, 2.2; 95% CI, 1.4 to 3.6), intermediate-2 (HR, 4.9; 95% CI, 3.2 to 7.7), and high-risk groups (HR, 10.7; 95% CI, 6.8 to 16.9), respectively (P < .001). Leukemia-free survival was predicted by the presence of thrombocytopenia or unfavorable karyotype (10-year risk of 31% v 12%; HR, 3.3; 95% CI, 1.9 to 5.6). Conclusion: DIPSS plus effectively combines prognostic information from DIPSS, karyotype, platelet count, and transfusion status to predict overall survival in PMF. In addition, unfavorable karyotype or thrombocytopenia predicts inferior leukemia-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationCervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationPassamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationMyelofibrosis with Myeloid Metaplasia
Tefferi, A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004273421706 · Cited by 740
Self-citationTefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationTefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citationTefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationPathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9316 · Cited by 289
Self-citationTefferi, A., Lasho, T. L., Huang, J., Finke, C., Mesa, R. A., Li, C. Y., Wu, W., Hanson, C. A., & Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2405097 · Cited by 251
Self-citationBarosi, G., Viarengo, G., Pecci, A., Rosti, V., Piaggio, G., Marchetti, M., & Frassoni, F. (2001) · Blood · doi:10.1182/blood.v98.12.3249 · Cited by 223
Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., et al. (2009) · Blood · doi:10.1182/blood-2009-04-216044 · Cited by 215
Risk factors for leukemic transformation in patients with primary myelofibrosis
Huang, J., Li, C., Mesa, R. A., Wu, W., Hanson, C. A., Pardanani, A. D., & Tefferi, A. (2008) · Cancer · doi:10.1002/cncr.23505 · Cited by 133
Self-citationHussein, K., Pardanani, A. D., Dyke, D. L. V., Hanson, C. A., & Tefferi, A. (2009) · Blood · doi:10.1182/blood-2009-08-240135 · Cited by 121
Self-citationTam, C. S. L., Kantarjian, H. M., Cortes, J. E., Lynn, A., Pierce, S. A., Zhou, L., Keating, M. J., Thomas, D. A., & Verstovšek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8833 · Cited by 119
Tefferi, A., Lasho, T. L., Patnaik, M. M., Finke, C. M., Hussein, K., Hogan, W. J., Elliott, M. A., Litzow, M. R., Hanson, C. A., & Pardanani, A. D. (2009) · Leukemia · doi:10.1038/leu.2009.225 · Cited by 105
Self-citationTam, C. S. L., Abruzzo, L. V., Lin, K. I., Cortes, J. E., Lynn, A., Keating, M. J., Thomas, D. A., Pierce, S. A., Kantarjian, H. M., & Verstovšek, S. (2009) · Blood · doi:10.1182/blood-2008-09-178541 · Cited by 92
Tefferi, A., Siragusa, S., Hussein, K., Schwager, S. M., Hanson, C. A., Pardanani, A. D., Cervantes, F., & Passamonti, F. (2009) · American Journal of Hematology · doi:10.1002/ajh.21574 · Cited by 79
Self-citationPrimary Chronic Myelofibrosis: Clinical and Prognostic Evaluation in 336 Japanese Patients
Okamura, T., Kinukawa, N., Niho, Y., & Mizoguchi, H. (2001) · International Journal of Hematology · doi:10.1007/bf02981937 · Cited by 72
Arora, B., Sirhan, S., Hoyer, J. D., Mesa, R. A., & Tefferi, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05280.x · Cited by 53
Self-citation
Cited by
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationTefferi, A., Guglielmelli, P., Larson, D. R., Finke, C., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 737
Self-citationTefferi, A., Rumi, E., Finazzi, G., Gisslinger, H., Vannucchi, A. M., Rodeghiero, F., Randi, M. L., Vaidya, R., Cazzola, M., Rambaldi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.163 · Cited by 700
Self-citationTefferi, A., Vaidya, R., Caramazza, D., Finke, C., Lasho, T., & Pardanani, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9490 · Cited by 608
Self-citationBarbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 566
Self-citation
Metadata
- Authors
- Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F., & Tefferi, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-01
- Volume
- 29
- Issue
- 4
- Pages
- 392-397
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2049965335
- Cited by
- 1,055
- References
- 19
- FWCI
- 21.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.